May 27, 2015 at 13:49 | Source: Moneycontrol.com
Emkay Global Financial Services has recommended to hold Divis Laboratories and State Bank of India (SBI) for the target price of Rs 1960 and Rs 308 respectively, in its research report dated May 25, 2015.
May 25, 2015 at 08:10 | Source: CNBC-TV18
ITC | SBI | MRPL | Hero Motocorp | Somany Ceramics | Henkel | NESCO | Divis Labs | Electrosteel Castings | CEAT | GHCL | Texmaco Rail | Natco Pharma | Radico Khaitan | Claris Life | Rane Brake Lining | SAIL | Sadbhav Engineering | Ipca Labs | Kernex Microsystems and BPCL are stocks, which are in the news today.
May 23, 2015 at 14:51 | Source: PTI
Consolidated total income from operations also rose to Rs 820.70 crore for the quarter under review against Rs 750.21 crore a year ago. For the full year 2014-15, the consolidated net profit rose to Rs 851.52 crore, from Rs 773.34 crore in the year-ago period.
May 18, 2015 at 14:45 | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com recommends buying Infosys, UPL and Divis Laboratories.
May 14, 2015 at 15:19 | Source: CNBC-TV18
Gaurav Bissa, Derivatives Analyst at LKP Securities recommends going long in Divis Laboratories for a target of Rs 1840-1850.
May 12, 2015 at 12:23 | Source: Moneycontrol.com
Divis Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 23, 2015, to consider and approve the audited financial results for the year ended March 31, 2015 and to recommend Dividend on Equity Shares for the year ended March 31, 2015, if any.
Apr 30, 2015 at 10:35 | Source: Moneycontrol.com
Auto stocks like Ashok Leyland, Maruti Suzuki India, TVS Motor Company, Hero Motocorp, Tata Motors will get astro support, says Satish Gupta of astrostocktips.
Apr 20, 2015 at 08:54 | Source: Moneycontrol.com
Pharma sector will continue getting strong astrological support. Buy Cipla, Glenmark Pharma, Sun Pharma, Divis Lab, Ajanta Pharma, Wockhardt etc, says Satish Gupta of Astrostocktips.
Apr 16, 2015 at 11:43 | Source: CNBC-TV18
Vineet Bhatnagar - MD at Phillip Capital expects 10-15 percent upside in midcap pharma stocks including Glenmark Pharma, Divis Laboratories, Torrent Pharma and Cadila Healthcare.
Apr 16, 2015 at 11:12 | Source: CNBC-TV18
Going ahead, Vineet Bhatnagar, managing director, Phillip Capital expects refinery, oil marketing companies and ONGC to show strong upward moves. He also sees another 10-15 percent upside in Glenmark, Torrent Pharma and Divis Lab.